Jubilant Cadista cleared after USFDA inspection

Jubilant Pharmova announced that its subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA, received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA) following an inspection in January 2025. The EIR signifies the successful closure of the inspection for the solid oral formulations facility in Salisbury, Maryland. The company clarified that the facility is not expected to resume manufacturing operations, aligning with a previous disclosure from April 18, 2024. Jubilant Cadista received the communication from USFDA on March 11, 2025, at 09:27 pm (IST). The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India's (Listing Obligations and Disclosure Requirements) Regulations, 2015.